These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 15816337)

  • 1. [Treatment of central precocious puberty with Gonadotropin-Releasing Hormone agonist (triptorelin) in girls: breast development, skeletal maturation, height and weight evolution during and after treatment].
    Messaaoui A; Massa G; Tenoutasse S; Heinrichs C
    Rev Med Brux; 2005 Feb; 26(1):27-32. PubMed ID: 15816337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idiopathic precocious puberty versus puberty in adopted children; auxological response to gonadotrophin-releasing hormone agonist treatment and final height.
    Kempers MJ; Otten BJ
    Eur J Endocrinol; 2002 Nov; 147(5):609-16. PubMed ID: 12444892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accelerated versus slowly progressive forms of puberty in girls with precocious and early puberty. Gonadotropin suppressive effect and final height obtained with two different analogs.
    Lanes R; Soros A; Jakubowicz S
    J Pediatr Endocrinol Metab; 2004 May; 17(5):759-66. PubMed ID: 15237711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in Precocious Puberty.
    Carel JC; Roger M; Ispas S; Tondu F; Lahlou N; Blumberg J; Chaussain JL
    J Clin Endocrinol Metab; 1999 Jun; 84(6):1973-8. PubMed ID: 10372696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Final height in central precocious puberty after long term treatment with a slow release GnRH agonist.
    Oostdijk W; Rikken B; Schreuder S; Otten B; Odink R; Rouwé C; Jansen M; Gerver WJ; Waelkens J; Drop S
    Arch Dis Child; 1996 Oct; 75(4):292-7. PubMed ID: 8984913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of complete and incomplete suppression of pituitary-gonadal activity in girls with central precocious puberty: influence on growth and predicted final height. The German-Dutch Precocious Puberty Study Group.
    Partsch CJ; Hümmelink R; Peter M; Sippell WG; Oostdijk W; Odink RJ; Drop SL
    Horm Res; 1993; 39(3-4):111-7. PubMed ID: 8262471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of GnRHa 3.75 mg subcutaneously every 6 weeks on adult height in girls with idiopathic central precocious puberty.
    Liang Y; Wei H; Li J; Hou L; Zhang J; Wu W; Ying Y; Luo X
    J Pediatr Endocrinol Metab; 2015 Jul; 28(7-8):839-46. PubMed ID: 25719299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females.
    Bertelloni S; Baroncelli GI; Sorrentino MC; Perri G; Saggese G
    Eur J Pediatr; 1998 May; 157(5):363-7. PubMed ID: 9625331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical study of subcutaneous administration of gonadotropin-releasing hormone agonist every six weeks in girls with idiopathic central precocious puberty].
    Liang Y; Wei H; Zhang JL; Hou L; Luo XP
    Zhonghua Er Ke Za Zhi; 2004 Nov; 42(11):845-9. PubMed ID: 15631714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty.
    Arrigo T; Cisternino M; Galluzzi F; Bertelloni S; Pasquino AM; Antoniazzi F; Borrelli P; Crisafulli G; Wasniewska M; De Luca F
    Eur J Endocrinol; 1999 Aug; 141(2):140-4. PubMed ID: 10427157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of central precocious puberty: lessons from a 15 years prospective trial. German Decapeptyl Study Group.
    Partsch CJ; Heger S; Sippell WG
    J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():747-58. PubMed ID: 10969917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined therapy with GnRH analog plus growth hormone in central precocious puberty.
    Pucarelli I; Segni M; Ortore M; Moretti A; Iannaccone R; Pasquino AM
    J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():811-20. PubMed ID: 10969926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Near final height after GnRH agonist treatment in central precocious puberty.
    Micillo M; Salerno M; Officioso A; Perna E; Gasparini N; Pisaturo L; Di Maio S
    J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():787-90. PubMed ID: 10969922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function.
    Heger S; Partsch CJ; Sippell WG
    J Clin Endocrinol Metab; 1999 Dec; 84(12):4583-90. PubMed ID: 10599723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Long-term experiences with a long-acting gonadotropin releasing hormone analog in therapy of central precocious puberty: effect on body growth].
    Hofmann-Ehrhart B; Schulz U; Kluge M; Wandl-Vergesslich K; Waldhauser F
    Wien Klin Wochenschr; 1995; 107(14):413-7. PubMed ID: 7668000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison between complete and incomplete suppression of the hypophyseal-gonadal axis in girls with central precocious puberty: effect on growth and prospective final height].
    Partsch CJ; Hümmelink R; Sippell WG; Oostdijk W; Odink RJ; Drop SL
    Monatsschr Kinderheilkd; 1993 Dec; 141(12):935-9. PubMed ID: 8114776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Central Precocious Puberty: Adult Height in Girls Treated with Quarterly or Monthly Gonadotropin-Releasing Hormone Analog Triptorelin.
    Bertelloni S; Massart F; Einaudi S; Wasniewska M; Miccoli M; Baroncelli GI
    Horm Res Paediatr; 2015; 84(6):396-400. PubMed ID: 26528763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of 6-month triptorelin formulation on predicted adult height and basal gonadotropin levels in patients with central precocious puberty.
    Yoo E; Kim S; Jung HL; Shim JY; Shim JW; Kim DS; Kwak JH; Kim ES; Yang A
    Front Endocrinol (Lausanne); 2023; 14():1134977. PubMed ID: 36875449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sexual precocity in boys: accelerated versus slowly progressive puberty gonadotropin-suppressive therapy and final height.
    Lazar L; Pertzelan A; Weintrob N; Phillip M; Kauli R
    J Clin Endocrinol Metab; 2001 Sep; 86(9):4127-32. PubMed ID: 11549638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gonadotropin-suppressive therapy in girls with early and fast puberty affects the pace of puberty but not total pubertal growth or final height.
    Lazar L; Kauli R; Pertzelan A; Phillip M
    J Clin Endocrinol Metab; 2002 May; 87(5):2090-4. PubMed ID: 11994346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.